Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.

Mattoo AR, Joun A, Jessup JM.

Mol Cancer Res. 2018 Sep 10. doi: 10.1158/1541-7786.MCR-18-0650. [Epub ahead of print]

PMID:
30201826
2.

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP.

JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580. Epub 2017 Jul 13.

3.

A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Keeney M, Wood BL, Hedley BD, DiGiuseppe JA, Stetler-Stevenson M, Paietta E, Lozanski G, Seegmiller AC, Greig BW, Shaver AC, Mukundan L, Higley HR, Sigman CC, Kelloff G, Jessup JM, Borowitz MJ.

Cytometry B Clin Cytom. 2018 Mar;94(2):239-249. doi: 10.1002/cyto.b.21528. Epub 2017 May 5.

PMID:
28475275
4.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

5.

Population-Based Lynch Syndrome Screening by Microsatellite Instability in Patients ≤50: Prevalence, Testing Determinants, and Result Availability Prior to Colon Surgery.

Karlitz JJ, Hsieh MC, Liu Y, Blanton C, Schmidt B, Jessup JM, Wu XC, Chen VW.

Am J Gastroenterol. 2015 Jul;110(7):948-55. doi: 10.1038/ajg.2014.417. Epub 2015 Jan 20.

PMID:
25601013
6.

Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system.

Chen VW, Hsieh MC, Charlton ME, Ruiz BA, Karlitz J, Altekruse SF, Ries LA, Jessup JM.

Cancer. 2014 Dec 1;120 Suppl 23:3793-806. doi: 10.1002/cncr.29056.

7.

Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.

Mattoo AR, Zhang J, Espinoza LA, Jessup JM.

Clin Cancer Res. 2014 Nov 1;20(21):5446-55. doi: 10.1158/1078-0432.CCR-14-1134. Epub 2014 Sep 10.

8.

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.

Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ.

Clin Cancer Res. 2014 Mar 15;20(6):1428-44. doi: 10.1158/1078-0432.CCR-13-2961.

9.

NANOG modulates stemness in human colorectal cancer.

Zhang J, Espinoza LA, Kinders RJ, Lawrence SM, Pfister TD, Zhou M, Veenstra TD, Thorgeirsson SS, Jessup JM.

Oncogene. 2013 Sep 12;32(37):4397-405. doi: 10.1038/onc.2012.461. Epub 2012 Oct 22.

10.

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS.

J Clin Oncol. 2012 Jul 1;30(19):2327-33. doi: 10.1200/JCO.2011.36.7136. Epub 2012 May 14.

11.

Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.

Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM.

Clin Cancer Res. 2012 Mar 15;18(6):1547-54. doi: 10.1158/1078-0432.CCR-11-2205.

12.

Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Williams PM, Lively TG, Jessup JM, Conley BA.

Clin Cancer Res. 2012 Mar 15;18(6):1531-9. doi: 10.1158/1078-0432.CCR-11-2203.

13.

Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.

Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM.

Clin Cancer Res. 2012 Mar 15;18(6):1515-23. doi: 10.1158/1078-0432.CCR-11-2206.

14.

Saturation diving alters folate status and biomarkers of DNA damage and repair.

Zwart SR, Jessup JM, Ji J, Smith SM.

PLoS One. 2012;7(2):e31058. doi: 10.1371/journal.pone.0031058. Epub 2012 Feb 7.

15.

'Evidence-based medicine: the time has come to set standards for staging'. Is a radical overhaul really needed?

Sobin LH, Compton CA, Gospodarowicz M, Greene FL, Gunderson LL, Jessup JM, Wittekind C.

J Pathol. 2010 Aug;221(4):361-2. doi: 10.1002/path.2729.

PMID:
20593484
16.

Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts.

Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Apr;134(4):e8-13. doi: 10.1043/1543-2165-134.4.e8. No abstract available.

PMID:
20367298
17.

Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts.

Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Apr;134(4):e19-24. doi: 10.1043/1543-2165-134.4.e19. No abstract available.

PMID:
20367295
18.

Protocol for the examination of specimens from patients with carcinoma of the intrahepatic bile ducts.

Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Vauthey JN; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Apr;134(4):e14-8. doi: 10.1043/1543-2165-134.4.e14. No abstract available.

PMID:
20367294
19.

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee.

Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9.

20.

Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach.

Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Feb;134(2):187-91. doi: 10.1043/1543-2165-134.2.187. No abstract available.

PMID:
20121605
21.

Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla.

Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Feb;134(2):181-6. doi: 10.1043/1543-2165-134.2.181. No abstract available.

PMID:
20121604
22.

Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum.

Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Feb;134(2):176-80. doi: 10.1043/1543-2165-134.2.176. No abstract available.

PMID:
20121603
23.

Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix.

Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2010 Feb;134(2):171-5. doi: 10.1043/1543-2165-134.2.171. No abstract available.

PMID:
20121602
24.

Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.

Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A.

J Clin Oncol. 2010 Jan 10;28(2):256-63. doi: 10.1200/JCO.2009.23.9194. Epub 2009 Nov 30.

25.

Revised TN categorization for colon cancer based on national survival outcomes data.

Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK.

J Clin Oncol. 2010 Jan 10;28(2):264-71. doi: 10.1200/JCO.2009.24.0952. Epub 2009 Nov 30.

26.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
27.

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR.

Oncogene. 2009 Feb 19;28(7):961-72. doi: 10.1038/onc.2008.448. Epub 2009 Jan 12.

28.

Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum.

Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Compton CC; Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2008 Jul;132(7):1182-93. doi: 10.1043/1543-2165(2008)132[1182:PFTEOS]2.0.CO;2. No abstract available. Erratum in: Arch Pathol Lab Med. 2008 Sep;132(9):1384.

PMID:
18605770
29.

Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.

Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, Jessup JM, Shetty K, Zasloff M, Mishra B, Reddy EP, Johnson L, Mishra L.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2445-50. doi: 10.1073/pnas.0705395105. Epub 2008 Feb 8.

30.

DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.

Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM.

Cancer Res. 2008 Feb 1;68(3):909-17. doi: 10.1158/0008-5472.CAN-06-1806.

31.
32.

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO.

J Clin Oncol. 2006 Nov 20;24(33):5313-27. Epub 2006 Oct 23.

PMID:
17060676
33.

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.

Jessup JM, Stewart A, Greene FL, Minsky BD.

JAMA. 2005 Dec 7;294(21):2703-11.

PMID:
16333005
34.

Carcinoembryonic antigen promotes tumor cell survival in liver through an IL-10-dependent pathway.

Jessup JM, Samara R, Battle P, Laguinge LM.

Clin Exp Metastasis. 2004;21(8):709-17.

PMID:
16035616
35.

Program for the Assessment of Clinical Cancer Tests (PACCT): implementing promising assays into clinical practice.

Jessup JM, Lively TG, Taube SE.

Expert Rev Mol Diagn. 2005 May;5(3):271-3. No abstract available.

PMID:
15934805
36.

Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma.

Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, Wellstein A, Maitra A, Riegel AT.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6134-42.

37.

Carcinoembryonic antigen induction of IL-10 and IL-6 inhibits hepatic ischemic/reperfusion injury to colorectal carcinoma cells.

Jessup JM, Laguinge L, Lin S, Samara R, Aufman K, Battle P, Frantz M, Edmiston KH, Thomas P.

Int J Cancer. 2004 Sep 1;111(3):332-7.

38.

Nitrosative stress in rotated three-dimensional colorectal carcinoma cell cultures induces microtubule depolymerization and apoptosis.

Laguinge LM, Lin S, Samara RN, Salesiotis AN, Jessup JM.

Cancer Res. 2004 Apr 15;64(8):2643-8.

39.

Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.

DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW.

Oncogene. 2003 Oct 30;22(49):7781-95.

PMID:
14586404
40.
41.

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA.

N Engl J Med. 2001 Sep 6;345(10):725-30.

42.

Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy.

Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, Jessup JM.

Cancer Gene Ther. 2001 Jun;8(6):397-404.

43.

NASA biotechnology: cell science in microgravity.

Jessup JM, Pellis NR.

In Vitro Cell Dev Biol Anim. 2001 Feb;37(2):2 p preceding 63. No abstract available.

PMID:
11332737
44.

Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells.

Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, Kim TH, Billiar TR, Song YK.

Oncogene. 2001 Mar 22;20(12):1476-85.

45.

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel.

J Clin Oncol. 2001 Mar 15;19(6):1865-78. Erratum in: J Clin Oncol 2001 Nov 1;19(21):4185-8. J Clin Oncol 2002 Apr 15;20(8):2213.

PMID:
11251019
46.

Microgravity culture reduces apoptosis and increases the differentiation of a human colorectal carcinoma cell line.

Jessup JM, Frantz M, Sonmez-Alpan E, Locker J, Skena K, Waller H, Battle P, Nachman A, Bhatti, Weber ME, Thomas DA, Curbeam RL Jr, Baker TL, Goodwin TJ.

In Vitro Cell Dev Biol Anim. 2000 Jun;36(6):367-73.

PMID:
10949995
47.

Carcinoembryonic antigen facilitates experimental metastasis through a mechanism that does not involve adhesion to liver cells.

Jessup JM, Ishii S, Mitzoi T, Edmiston KH, Shoji Y.

Clin Exp Metastasis. 1999;17(6):481-8.

PMID:
10763913
48.

Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer.

Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM.

Ann Surg Oncol. 2000 Mar;7(2):133-8.

PMID:
10761792
49.

Tumor markers--prognostic and therapeutic implications for colorectal carcinoma.

Jessup JM.

Surg Oncol. 1998 Nov-Dec;7(3-4):139-51. Review.

PMID:
10677165
50.

Reactive nitrogen and oxygen radicals formed during hepatic ischemia-reperfusion kill weakly metastatic colorectal cancer cells.

Jessup JM, Battle P, Waller H, Edmiston KH, Stolz DB, Watkins SC, Locker J, Skena K.

Cancer Res. 1999 Apr 15;59(8):1825-9.

Supplemental Content

Loading ...
Support Center